Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Jonathan Alspaugh currently holds 165,372 shares of Aeglea BioTherapeutics, Inc. (AGLE), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Jonathan Alspaugh has been a net buyer of AGLE stock. They have purchased $604.7K and sold $0 worth of shares.
Jonathan Alspaugh's most recent insider trade was on Mar 11, 2022, when they purchased 75,000 shares at $2.08 per share.
Jonathan Alspaugh serves as Executive at Aeglea BioTherapeutics, Inc. (AGLE). They have executed 5 insider transactions totaling $604.7K over their tenure at the company.
Jonathan Alspaugh holds the position of Executive at Aeglea BioTherapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 5 years and currently hold a stake valued at $0.
Jonathan Alspaugh has shown a buying trading pattern, with $604.7K in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Jonathan Alspaugh was on Dec 9, 2021, when they purchased $186.0K worth of AGLE shares. This transaction involved 50,000 shares at $3.72 per share.
Jonathan Alspaugh currently owns 165,372 shares of Aeglea BioTherapeutics, Inc. (AGLE), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Jonathan Alspaugh's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Jonathan Alspaugh has 5 Form 4 filings on record as an insider at Aeglea BioTherapeutics, Inc..
Set alerts for Jonathan Alspaugh and 40,000+ other insiders.